BioCentury
ARTICLE | Clinical News

Pariet rabeprazole: Phase III started

August 12, 2013 7:00 AM UTC

Eisai disclosed in its 1Q13 earnings for the period ending June 30 that it began a Japanese Phase III trial to evaluate Pariet rabeprazole in patients resistant to PPIs. Eisai co-promotes a 20 mg tabl...